Evidence map›Paper›PMID 23945385›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2013

microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer.

Riccardo Cazzoli, Fiamma Buttitta, Marta Di Nicola, Sara Malatesta, Antonio Marchetti, William N Rom, Harvey I Pass

2 registry-linked trialsAbstract read
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 270 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
270citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04499794 unknown statusnot on this mapstarted 2020, after this paper: background citation

The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring

TypeobservationalSponsorChinese Academy of Medical SciencesRan2020 to 2025Enrolled75ConditionsUntreated Advanced NSCLC Patients, FISH Identified ALK Fusion Positive or NegativeArmsALK inhibitor
NCT05854030 unknown statusnot on this mapstarted 2022, after this paper: background citation

A Study on Serum Exosomal miRNA Predicting the Effective and Prognosis of Immunotherapy Combined With Chemotherapy in Pulmonary Squamous Carcinoma

TypeobservationalSponsorTianjin Medical University Cancer Institute and HospitalRan2022 to 2023Enrolled60ConditionsLung Neoplasm, Squamous Cell Carcinoma, ExosomesArmscollect plasma samples and clinical features
3 · Its place in the literature

Who cites it

270 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Review
  10. Review
  11. Review
  12. Urinary biomarkers for lung cancer detection.The journal of liquid biopsy · 2026
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

210 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Riccardo CazzoliCenter of Predictive Molecular Medicine, Center of Excellence on Aging, †Oncological and Cardiovascular Molecular Medicine Unit, University-Foundation, Chieti, Italy.
Fiamma Buttitta
Marta Di Nicola
Sara Malatesta
Antonio Marchetti
William N Rom
Harvey I Pass

Funding

The North American Mesothelioma ConsortiumU01CA111295 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HUFLEJT, MARGARET ELISABETH, PASS, HARVEY IRA · 2005 to 2016
$4.8M
NCI NIH HHS 2U01CA111295-04NCI NIH HHS U01CA086/37NCI NIH HHS U01 CA111295
6 · The paper itself

Abstract

introductionLung cancer is the highest cause of mortality among tumor pathologies worldwide. There are no validated techniques for an early detection of pulmonary cancer lesions other than low-dose helical computed tomography scan. Unfortunately, this method has some negative effects. Recent studies have laid the basis for development of exosomes-based techniques to screen/diagnose lung cancers. As the isolation of circulating exosomes is a minimally invasive procedure, this technique opens new possibilities for diagnostic applications.

methodsWe used a first set of 30 plasma samples from as many patients, including 10 patients affected by lung adenocarcinomas, 10 with lung granulomas, and 10 healthy smokers matched for age and sex as negative controls. Wide-range microRNAs analysis (742 microRNAs) was performed by quantitative real time polymerase chain reaction. Data were compared on the basis of lesion characteristics, using WEKA software for statistics and modeling. Subsequently, selected microRNAs were evaluated on an independent larger group of samples (105 specimens: 50 lung adenocarcinomas, 30 lung granulomas, and 25 healthy smokers).

resultsThis analysis led to the selection of four microRNAs to perform a screening test (miR-378a, miR-379, miR-139-5p, and miR-200b-5p), useful to divide population into two groups: nodule (lung adenocarcinomas + carcinomas) and non-nodule (healthy former smokers). Six microRNAs (miR-151a-5p, miR-30a-3p, miR-200b-5p, miR-629, miR-100, and miR-154-3p) were selected for a second test on the nodule population to discriminate between lung adenocarcinoma and granuloma.

conclusionsThe screening test showed 97.5% sensitivity, 72.0% specificity, and area under the curve receiver operating characteristic of 90.8%. The diagnostic test had 96.0% sensitivity, 60.0% specificity, and area under the curve receiver operating characteristic of 76.0%. Further evaluation is needed to confirm the predictive power of these models on larger cohorts of samples.

Indexed as

Mass ScreeningAdenocarcinomaAdultAgedAged, 80 and overBiomarkers, TumorCase-Control StudiesEarly Detection of CancerExosomesFemaleFollow-Up StudiesGranulomaHumansLung NeoplasmsMaleMicroRNAsBiomarkers, TumorMicroRNAs

Identifiers

PMID23945385
PMCPMC4123222

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.